Related references
Note: Only part of the references are listed.Pancreatic adenocarcinoma: Beyond first line, where are we?
Sara Cherri et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2021)
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
Masashi Sawada et al.
BMC CANCER (2020)
FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure
Toshihiko Matsumoto et al.
PANCREAS (2020)
FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan
Noritoshi Kobayashi et al.
PANCREATOLOGY (2020)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Multicenter phase. trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
Moon Jae Chung et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study
Jung Hoon Kim et al.
CANCER COMMUNICATIONS (2018)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al.
LANCET (2017)
Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
T. Ioka et al.
BRITISH JOURNAL OF CANCER (2017)
A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer
M. Ueno et al.
ANNALS OF ONCOLOGY (2016)
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
Sharlene Gill et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam et al.
LANCET (2016)
Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer
S. Ohkawa et al.
BRITISH JOURNAL OF CANCER (2015)
Phase II study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
Takuji Okusaka et al.
CANCER SCIENCE (2014)
Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
Helmut Oettle et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
S-1 as Monotherapy or in Combination With Leucovorin as Second-Line Treatment in Gemcitabine-Refractory Advanced Pancreatic Cancer: A Randomized, Open-Label, Multicenter, Phase II Study
Feijiao Ge et al.
ONCOLOGIST (2014)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer
David Cella et al.
QUALITY OF LIFE RESEARCH (2013)
Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer
Kentaro Sudo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
Chigusa Morizane et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma
JL Steel et al.
ANNALS OF ONCOLOGY (2006)
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer
AH Ko et al.
BRITISH JOURNAL OF CANCER (2005)
Measuring health-related quality of life in patients with hepatobiliary cancers: The functional assessment of cancer therapy-hepatobiliary questionnaire
N Heffernan et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
